Cancer risk in relatives of BRCA1/2 pathogenic variant carriers in a large series of unselected patients with breast cancer

被引:1
作者
Liu, Jiaming [1 ]
Yao, Lu [1 ]
Sun, Jie [1 ]
Hu, Li [1 ]
Chen, Jiuan [1 ]
Zhang, Juan [1 ]
Xu, Ye [1 ]
Xie, Yuntao [1 ]
机构
[1] Peking Univ, Canc Hosp & Inst, Familial & Hereditary Canc Ctr, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
基金
中国国家自然科学基金;
关键词
BRCA1; variant; BRCA2; cancer risk in relatives; Chinese breast cancer patients; family history of cancer; GERMLINE MUTATIONS; BRCA2; MUTATIONS; CHINESE WOMEN; COHORT;
D O I
10.20892/j.issn.2095-3941.2022.0593
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The spectrum and risk of cancer in relatives of BRCA1/2 pathogenic variant carriers in the Chinese population have not been established.Methods: A family history of cancer in 9903 unselected breast cancer patients was retrospectively analyzed. BRCA1/2 status was determined for all patients and relative risks (RRs) were calculated to evaluate cancer risk in relatives of the patients.Results: The incidences of breast cancer in female relatives of BRCA1 carriers, BRCA2 carriers, and non-carriers were 33.0%, 32.2%, and 7.7%, respectively. The corresponding incidences of ovarian cancer were 11.5%, 2.4%, and 0.5%, respectively. The incidences of pancreatic cancer in male relatives of BRCA1 carriers, BRCA2 carriers, and non-carriers were 1.4%, 2.7%, and 0.6%, respectively. The corresponding incidences of prostate cancer were 1.0%, 2.1%, and 0.4%, respectively. The risks of breast and ovarian cancers in female relatives of BRCA1 and BRCA2 carriers were significantly higher than female relatives of non-carriers (BRCA1: RR = 4.29, P < 0.001 and RR = 21.95, P < 0.001; BRCA2: RR = 4.19, P < 0.001 and RR = 4.65, P < 0.001, respectively). Additionally, higher risks of pancreatic and prostate cancers were noted in male relatives of BRCA2 carriers than non-carriers (RR = 4.34, P = 0.001 and RR = 4.86, P = 0.001, respectively). Conclusions: Female relatives of BRCA1 and BRCA2 carriers are at increased risk for breast and ovarian cancers, and male relatives of BRCA2 carriers are at increased risk for pancreatic and prostate cancers.
引用
收藏
页码:147 / 154
页数:8
相关论文
共 30 条
  • [1] Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310
  • [2] Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365
  • [3] Cancer Statistics in China, 2015
    Chen, Wanqing
    Zheng, Rongshou
    Baade, Peter D.
    Zhang, Siwei
    Zeng, Hongmei
    Bray, Freddie
    Jemal, Ahmedin
    Yu, Xue Qin
    He, Jie
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) : 115 - 132
  • [4] BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees
    Cortesi, Laura
    Domati, Federica
    Guida, Annalisa
    Marchi, Isabella
    Toss, Angela
    Barbieri, Elena
    Marcheselli, Luigi
    Venturelli, Marta
    Piana, Simonetta
    Cirilli, Claudia
    Federico, Massimo
    [J]. CANCER BIOLOGY & MEDICINE, 2021, 18 (02) : 470 - 476
  • [5] Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis
    Cullinane, C. M.
    Creavin, B.
    O'Connell, E. P.
    Kelly, L.
    O'Sullivan, M. J.
    Corrigan, M. A.
    Redmond, H. P.
    [J]. BRITISH JOURNAL OF SURGERY, 2020, 107 (08) : 951 - 959
  • [6] Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women
    Fu, Fenfen
    Zhang, Dongjie
    Hu, Li
    Sundaram, Senthil
    Ying, Dingge
    Zhang, Ying
    Fu, Shuna
    Zhang, Juan
    Yao, Lu
    Xu, Ye
    Xie, Yuntao
    [J]. CANCER BIOLOGY & MEDICINE, 2022, 19 (02) : 253 - +
  • [7] Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
    Gallagher, David J.
    Gaudet, Mia M.
    Pal, Prodipto
    Kirchhoff, Tomas
    Balistreri, Lisa
    Vora, Kinjal
    Bhatia, Jasmine
    Stadler, Zsofia
    Fine, Samson W.
    Reuter, Victor
    Zelefsky, Michael
    Morris, Michael J.
    Scher, Howard I.
    Klein, Robert J.
    Norton, Larry
    Eastham, James A.
    Scardino, Peter T.
    Robson, Mark E.
    Offit, Kenneth
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (07) : 2115 - 2121
  • [8] BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study
    Kitson, Sarah J.
    Bafligil, Cemsel
    Ryan, Neil A. J.
    Lalloo, Fiona
    Woodward, Emma R.
    Clayton, Richard D.
    Edmondson, Richard J.
    Bolton, James
    Crosbie, Emma J.
    Evans, D. Gareth
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 136 : 169 - 175
  • [9] Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
    Kuchenbaecker, Karoline B.
    Hopper, John L.
    Barnes, Daniel R.
    Phillips, Kelly-Anne
    Mooij, Thea M.
    Roos-Blom, Marie-Jose
    Jervis, Sarah
    van Leeuwen, Flora E.
    Milne, Roger L.
    Andrieu, Nadine
    Goldgar, David E.
    Terry, Mary Beth
    Rookus, Matti A.
    Easton, Douglas F.
    Antoniou, Antonis C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (23): : 2402 - 2416
  • [10] Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030
    Lei, Shaoyuan
    Zheng, Rongshou
    Zhang, Siwei
    Chen, Ru
    Wang, Shaoming
    Sun, Kexin
    Zeng, Hongmei
    Wei, Wenqiang
    He, Jie
    [J]. CANCER BIOLOGY & MEDICINE, 2021, 18 (03) : 900 - +